Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Levomilnacipran (Fetzima) a new SNRI for depression.

[No authors listed]

Med Lett Drugs Ther. 2013 Dec 23;55(1432):101-2. No abstract available.

PMID:
24419243
2.

Levomilnacipran: a newly approved drug for treatment of major depressive disorder.

Mago R, Mahajan R, Thase ME.

Expert Rev Clin Pharmacol. 2014 Mar;7(2):137-45. doi: 10.1586/17512433.2014.889563. Review.

PMID:
24524592
3.

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E.

Hum Psychopharmacol. 2004 Dec;19(8):585-6. No abstract available.

PMID:
15570574
4.

Milnacipran for fibromyalgia.

Dempsey J.

Issues Emerg Health Technol. 2008 Feb;(114):1-4.

PMID:
18354855
5.

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

Sambunaris A, Gommoll C, Chen C, Greenberg WM.

Int Clin Psychopharmacol. 2014 Jul;29(4):197-205. doi: 10.1097/YIC.0000000000000033.

6.

Milnacipran and selective serotonin reuptake inhibitors in major depression.

Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. Review.

PMID:
8923126
7.

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.

Kasper S, Pletan Y, Solles A, Tournoux A.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:35-9. Review.

PMID:
8923125
8.

Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.

Yoshida K, Higuchi H, Ozaki N.

Pharmacopsychiatry. 2007 Mar;40(2):84-5. No abstract available.

PMID:
17447181
9.

Raynaud's syndrome in a patient treated with milnacipran.

Bourgade B, Jonville-Béra AP, Le Garé C, Ferquel D, Autret-Leca E.

Ann Pharmacother. 1999 Sep;33(9):1009-10. No abstract available.

PMID:
10492510
10.
11.

Fluoxetine: new indication. Depression in children: too many uncertainties.

[No authors listed]

Prescrire Int. 2008 Oct;17(97):186-7. No abstract available.

PMID:
19534039
12.

How have the SSRI antidepressants affected suicide risk?

Hall WD.

Lancet. 2006 Jun 17;367(9527):1959-62. No abstract available.

PMID:
16782468
13.

[The use of antidepressants to treat depression in children and adolescents].

Desombre H, Paccalin C, Revol O, Fourneret P.

Arch Pediatr. 2006 Jun;13(6):711-3. Epub 2006 May 12. French. No abstract available.

PMID:
16697608
14.

Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide?

Healy D.

Can J Psychiatry. 2009 Feb;54(2):69-71; discussion 76-7. No abstract available. Erratum in: Can J Psychiatry. 2009 May;54(5):350.

PMID:
19254434
15.

Efficacy and tolerability of milnacipran: an overview.

Montgomery SA, Prost JF, Solles A, Briley M.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:47-51. Review.

PMID:
8923127
16.
17.

LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.

Zadka Ł, Dziwota E, Olajossy M.

Acta Pol Pharm. 2016 Mar-Apr;73(2):285-9. Review.

PMID:
27180420
18.

Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.

Scott LJ.

CNS Drugs. 2014 Nov;28(11):1071-82. doi: 10.1007/s40263-014-0203-1. Review.

PMID:
25270036
19.

Clinical efficacy of milnacipran: placebo-controlled trials.

Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:29-33. Review.

PMID:
8923124
20.

A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.

Steen A, Den Boer JA.

Int Clin Psychopharmacol. 1997 Sep;12(5):269-81.

PMID:
9466161
Items per page

Supplemental Content

Write to the Help Desk